Lead: The Centers for Disease Control and Prevention has formally rescinded its decades-long universal recommendation that all newborns receive a hepatitis B vaccine within 24 hours of birth. The agency’s vaccine advisory committee, reconstituted this year by Health Secretary Robert F. Kennedy Jr., voted for the change in early December and Acting CDC Director Jim O’Neill accepted the panel’s recommendation. The new guidance advises parents of mothers who test negative for hepatitis B to consult clinicians about timing; infants of mothers who are positive or whose status is unknown should still receive the birth dose.
Key Takeaways
- CDC ended its universal birth-dose recommendation this month after the Advisory Committee on Immunization Practices voted to change policy; Acting Director Jim O’Neill accepted the recommendation.
- The agency had recommended a hepatitis B vaccine within 24 hours of birth since 1991, a policy tied to a 99% drop in pediatric acute hepatitis B from 1990 to 2019.
- Under the new guidance, infants of mothers who test negative may wait until at least 2 months for the first dose; infants of mothers who are positive or whose status is unknown should still receive a dose within 24 hours.
- The ACIP also proposed, and CDC is reviewing, a secondary suggestion that parents consider testing children for hepatitis B antibodies before deciding on subsequent doses.
- Many public-health experts, medical societies and clinicians have publicly urged the CDC to keep the birth-dose recommendation, warning that delays could increase perinatal transmission and long-term liver disease.
- The Department of Health and Human Services says insurance coverage and the Vaccines for Children Program will continue to cover hepatitis B shots for newborns.
Background
Universal newborn hepatitis B vaccination became CDC policy in 1991, aimed primarily at preventing mother-to-child transmission at birth and reducing lifelong chronic infections that can lead to cirrhosis and liver cancer. The birth dose was adopted after evidence showed perinatal transmission was a major driver of chronic hepatitis B in the United States and that timely vaccination sharply reduced pediatric cases.
From 1990 to 2019, reported pediatric acute hepatitis B cases fell by roughly 99%, a decline widely attributed to routine newborn immunization and expanded prenatal screening. Public-health programs also rely on the birth dose to protect infants when maternal screening is incomplete or when mothers’ infection status is not available at delivery.
Earlier this year, Health Secretary Robert F. Kennedy Jr. dismissed much of the long-standing membership of the CDC’s Advisory Committee on Immunization Practices (ACIP) and appointed new members. Those personnel changes preceded the committee’s recent reassessment of the hepatitis B birth-dose recommendation.
Main Event
In a December meeting of ACIP, members voted to shift from a universal birth-dose recommendation to guidance that emphasizes parental discussion and clinician judgment for infants whose mothers test negative for hepatitis B. Acting CDC Director Jim O’Neill announced on a Tuesday this month that he would accept the panel’s recommendation, making it agency policy.
The revised guidance keeps a firm recommendation for infants born to mothers who are hepatitis B surface antigen–positive or whose status is unknown: these infants should receive the first vaccine dose within 24 hours of birth and appropriate follow-up. For other newborns, CDC now advises parents to discuss timing with their health care providers and suggests the first dose can be given at or after 2 months if the birth dose is deferred.
The advisory panel also advanced a secondary proposal that parents might consider testing children for hepatitis B antibodies before completing the vaccine series; CDC said it is still reviewing that suggestion. Hepatitis B vaccination for infants is customarily a three-dose series, with timing varying by whether a birth dose is given.
The committee’s deliberations drew sustained criticism from many public-health officials and clinicians during and after the meeting, who argued the panel relied on selective evidence and allowed misinformation to influence discussion. Despite those objections, the CDC finalized the policy change when leadership accepted the recommendation.
Analysis & Implications
Public-health specialists warn that removing a universal recommendation may increase the risk of perinatal hepatitis B transmission, especially where maternal screening is incomplete. Because hepatitis B infection acquired at birth has a high likelihood of becoming chronic, even a small rise in transmission could translate into more cases of chronic liver disease and cancer decades later.
The birth-dose policy functioned as a safety net for gaps in prenatal testing and documentation. In many hospitals, newborn vaccination at birth ensures protection for infants whose mothers were not screened during pregnancy or whose results were unavailable at delivery; changing the recommendation shifts responsibility toward pre-delivery screening systems and outpatient follow-up.
The policy shift also reflects broader tensions about the CDC’s credibility among clinicians and state health departments. Since the ACIP membership overhaul, several states and professional groups have signaled they will continue to follow established medical-society guidance rather than the agency’s revised stance, potentially creating a patchwork of practice across jurisdictions.
Economically, any increase in chronic hepatitis B cases would raise long-term health-care costs tied to monitoring, antiviral therapy and management of liver complications. Short-term costs are likely to be limited because federal programs will continue to finance vaccines for eligible infants and insurers have been told coverage is unaffected.
Comparison & Data
| Metric | 1990 | 2019 | Change |
|---|---|---|---|
| Pediatric acute hepatitis B cases (reported) | Baseline | ~1% of 1990 levels | −99% |
The 99% reduction in reported pediatric acute cases from 1990 to 2019 is frequently cited as evidence of the birth-dose strategy’s population impact. That decline occurred alongside expanded prenatal screening and other public-health measures; disentangling their relative contributions requires careful epidemiologic analysis. Still, the rapid fall in pediatric cases after universal vaccination was introduced is a central datum in the debate over the birth dose.
Reactions & Quotes
“We are restoring the balance of informed consent to parents whose newborns face little risk of contracting hepatitis B.”
Jim O’Neill, Acting CDC Director (statement)
O’Neill framed the change as a shift toward parental decision-making for low-risk births, emphasizing informed consent as a rationale for revising the recommendation.
“Ending the recommendation for newborns makes it more likely the number of cases will begin to increase again. This makes America sicker.”
Sen. Bill Cassidy (physician, public statement)
Sen. Cassidy, a liver specialist, was among clinicians who warned that the policy could reverse public-health gains and urged CDC leadership to retain the birth-dose recommendation.
“The American Academy of Pediatrics continues to recommend a first dose of hepatitis B vaccine within 24 hours of birth.”
American Academy of Pediatrics (position)
The AAP’s stance demonstrates that major pediatric professional societies remain aligned with the earlier universal recommendation, and many clinicians say they will continue to advise immediate newborn vaccination.
Unconfirmed
- Claims that breaking up the combined MMR vaccine into separate shots would improve safety lack supporting evidence and remain unproven.
- Suggestions that acetaminophen use in pregnancy definitively causes autism are not established; large bodies of research have not confirmed a causal link.
- The advisory panel’s recommendation that parents consider antibody testing before additional doses is a proposal under review and is not yet supported by consensus evidence on population-level benefits.
Bottom Line
The CDC’s decision to end a universal birth-dose recommendation for hepatitis B marks a substantive change in federal immunization policy and departs from long-standing public-health practice. While infants of mothers who are known to be infected will still receive immediate protection, the new guidance places greater emphasis on prenatal screening and parental-clinician discussion for low-risk births.
The change may produce divergent practices across hospitals and states, because major pediatric societies and many clinicians continue to support the birth dose. Public-health authorities will need to monitor newborn vaccination coverage, perinatal infection rates and prenatal screening completeness closely to detect any reversal of the declines achieved since the early 1990s.